Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

32
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
32
Menopause01:28

Menopause

5.0K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

2.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study.

Journal of neurology·2026
Same author

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Lancet (London, England)·2026
Same author

Large language models to infer depression in patients with neurological conditions.

BMJ neurology open·2026
Same author

Beyond chronological age: biological aging and its relevance for motor and cognitive function in multiple sclerosis.

Neurodegenerative disease management·2026
Same author

Closing the referral gap: The role of a quality improvement initiative to enhance pelvic health physical therapy referrals for persons with multiple sclerosis-related bladder symptoms.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

Identifying knowledge gaps in reproductive health management for women with multiple sclerosis and healthcare professionals: a scoping review.

Frontiers in neurology·2026

Related Experiment Video

Updated: May 7, 2026

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.6K

Menopause in multiple sclerosis: therapeutic considerations.

Riley Bove1, Tanuja Chitnis, Maria Houtchens

  • 1Department of Neurology, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, 1 Brookline Place West, Suite 225, Brookline, MA, 02445, USA, rbove@partners.org.

Journal of Neurology
|October 9, 2013
PubMed
Summary
This summary is machine-generated.

Women with multiple sclerosis (MS) often experience overlapping symptoms during perimenopause. This review covers managing these shared symptoms and discusses screening needs and research gaps for MS during menopause.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K

Related Experiment Videos

Last Updated: May 7, 2026

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.6K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K

Area of Science:

  • Neurology
  • Immunology
  • Women's Health

Background:

  • Multiple sclerosis (MS) onset is typically in childbearing years, but many patients reach perimenopausal age.
  • Menopausal and MS symptoms frequently overlap, including sexual dysfunction, mood disorders, and bladder issues.
  • Perimenopausal changes like hot flashes and sleep disturbances can worsen MS symptoms.

Purpose of the Study:

  • To review immunological and neurological changes during menopause and their impact on MS.
  • To discuss management strategies for common overlapping symptoms.
  • To highlight screening needs and research gaps concerning menopause and MS.

Main Methods:

  • Literature review of immunological and neurological changes during menopause.
  • Synthesis of common symptoms and their management (behavioral and pharmacological).
  • Discussion of screening guidelines for osteoporosis and cancer.
  • Identification of research gaps regarding menopausal transition effects on MS disease course and hormone replacement therapy.

Main Results:

  • Menopause involves immunological and neurological shifts that can influence MS.
  • Common symptoms like fatigue, depression, sexual dysfunction, pain, and insomnia require integrated management.
  • Perimenopausal women with MS need specific screening for osteoporosis and cancer.
  • Significant research gaps exist regarding menopause's effect on MS progression and the role of hormone therapy.

Conclusions:

  • Neurologists play a key role in managing overlapping menopausal and MS symptoms.
  • Integrated management strategies and appropriate screenings are crucial for perimenopausal women with MS.
  • Further research is needed to understand the menopausal transition's impact on MS and the potential benefits of hormone replacement therapy.